Wellington Shields & Co. LLC grew its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.6% through the 2nd quarter, in keeping with its most up-to-date Kind 13F submitting with the Securities and Alternate Fee (SEC). The fund owned 15,845 shares of the corporate’s inventory after buying a further 250 shares through the quarter. Johnson & Johnson makes up roughly 0.8% of Wellington Shields & Co. LLC’s portfolio, making the inventory its twenty fifth largest holding. Wellington Shields & Co. LLC’s holdings in Johnson & Johnson had been price $2,316,000 as of its most up-to-date SEC submitting.
A variety of different hedge funds have additionally modified their holdings of the enterprise. Residents & Northern Corp elevated its stake in shares of Johnson & Johnson by 3.5% within the 2nd quarter. Residents & Northern Corp now owns 1,884 shares of the corporate’s inventory valued at $275,000 after shopping for a further 63 shares through the interval. Carolinas Wealth Consulting LLC raised its holdings in Johnson & Johnson by 0.4% through the 4th quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the corporate’s inventory price $2,643,000 after buying a further 64 shares over the past quarter. Epic Belief Funding Advisors LLC lifted its place in Johnson & Johnson by 3.6% through the 2nd quarter. Epic Belief Funding Advisors LLC now owns 1,831 shares of the corporate’s inventory valued at $268,000 after buying a further 64 shares through the interval. Verity Asset Administration Inc. boosted its stake in shares of Johnson & Johnson by 2.0% within the 4th quarter. Verity Asset Administration Inc. now owns 3,268 shares of the corporate’s inventory valued at $512,000 after buying a further 65 shares over the past quarter. Lastly, Clothes shop Monetary LLC raised its stake in shares of Johnson & Johnson by 0.4% through the second quarter. Clothes shop Monetary LLC now owns 16,632 shares of the corporate’s inventory price $2,431,000 after shopping for a further 65 shares over the past quarter. 69.55% of the inventory is owned by hedge funds and different institutional traders.
Johnson & Johnson Buying and selling Down 0.1 %
Johnson & Johnson inventory opened at $164.64 on Friday. The corporate has a market cap of $396.24 billion, a price-to-earnings ratio of 10.26, a P/E/G ratio of two.71 and a beta of 0.53. The agency has a 50-day transferring common of $159.17 and a 200-day transferring common of $154.00. The corporate has a debt-to-equity ratio of 0.44, a present ratio of 1.07 and a fast ratio of 0.85. Johnson & Johnson has a one yr low of $143.13 and a one yr excessive of $168.85.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final posted its quarterly earnings outcomes on Wednesday, July seventeenth. The corporate reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. The agency had income of $22.45 billion for the quarter, in comparison with analyst estimates of $22.33 billion. Johnson & Johnson had a return on fairness of 36.60% and a web margin of 46.34%. The enterprise’s quarterly income was up 4.3% on a year-over-year foundation. Throughout the identical quarter within the earlier yr, the agency earned $2.80 EPS. On common, equities analysts anticipate that Johnson & Johnson will submit 10.02 earnings per share for the present fiscal yr.
Johnson & Johnson Dividend Announcement
The corporate additionally lately disclosed a quarterly dividend, which was paid on Tuesday, September tenth. Stockholders of file on Tuesday, August twenty seventh got a $1.24 dividend. This represents a $4.96 dividend on an annualized foundation and a dividend yield of three.01%. The ex-dividend date was Tuesday, August twenty seventh. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.
Wall Road Analysts Forecast Development
A variety of analysis companies have lately weighed in on JNJ. Royal Financial institution of Canada reissued an “outperform” score and issued a $175.00 value goal on shares of Johnson & Johnson in a analysis be aware on Tuesday, July thirtieth. TD Cowen lowered their value goal on shares of Johnson & Johnson from $195.00 to $185.00 and set a “purchase” score for the corporate in a analysis report on Thursday, July 18th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” score to a “impartial” score and decreased their goal value for the inventory from $160.00 to $150.00 in a report on Tuesday, July twenty third. StockNews.com lowered Johnson & Johnson from a “strong-buy” score to a “purchase” score in a analysis report on Friday, September sixth. Lastly, Sanford C. Bernstein elevated their goal value on Johnson & Johnson from $161.00 to $171.00 in a analysis be aware on Thursday, July 18th. Seven funding analysts have rated the inventory with a maintain score and 7 have assigned a purchase score to the corporate. In keeping with MarketBeat, the corporate presently has a median score of “Reasonable Purchase” and a median goal value of $173.21.
Verify Out Our Newest Evaluation on JNJ
Insider Exercise
In different Johnson & Johnson information, VP Robert J. Decker bought 5,635 shares of the enterprise’s inventory in a transaction that occurred on Friday, August thirtieth. The inventory was bought at a median value of $165.06, for a complete transaction of $930,113.10. Following the transaction, the vice chairman now owns 18,973 shares of the corporate’s inventory, valued at $3,131,683.38. The sale was disclosed in a doc filed with the SEC, which is obtainable by this hyperlink. 0.16% of the inventory is owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare area worldwide. The corporate’s Revolutionary Drugs phase presents merchandise for numerous therapeutic areas, akin to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious illnesses comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, akin to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Additional Studying
Obtain Information & Scores for Johnson & Johnson Each day – Enter your e mail tackle under to obtain a concise each day abstract of the newest information and analysts’ scores for Johnson & Johnson and associated corporations with MarketBeat.com’s FREE each day e mail publication.
